Plasma clearance of an antibody—enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo

GT Rogers, PJ Burke, SK Sharma, R Koodie and JA Boden

Correspondence: Dr GT Rogers
Received 31 May 1995; revised 27 July 1995; accepted 2 August 1995

Summary The effect of anti-enzyme antibody clearance on prodrug turnover in antibody-directed enzyme prodrug therapy (ADEPT) has been studied. Mice bearing LS174T xenografts were given localising carboxypeptidase G₂ (CPG₂) conjugate (AEC) and 19 h later galactosylated anti-CPG₂ antibody (SB43-GAL). In regimen 1 prodrug was injected 5 h after SB43-GAL as previously described. In regimen 2, very high active drug levels were found in the liver, showing removal of AEC from the blood followed by reactive enzyme and extensive and rapid prodrug turnover. Active drug levels in tumour and blood reached similar peak levels to those of the control. Regimen 3 resulted in lower active drug levels in tissues, consistent with degradation and excretion of enzyme. Regimen 3 also produced the best tumour to normal ratios for active drug. Residual prodrug in tumour was unaffected by SB43-GAL, showing the advantage of galactosylation in minimising inactivation of CPG in tumour. By contrast, residual prodrug in blood persisted for longer when SB43-GAL was used. Circulatory clearance of enzyme with SB43-GAL allows prodrug to be administered expeditiously with reduced toxicity and with the prospect of increasing the dosage.

Keywords: ADEPT; clearance; prodrug; targeting; carboxypeptidase G₂

The generation of cytotoxic agents from prodrugs selectively in tumour tissue would be an important step forward in the chemotherapy of cancer (Bagshawe, 1987; Bagshawe et al., 1988). Monoclonal antibodies against a tumour marker could provide the essential targeting agent to carry the means to effect prodrug activation and result in accumulation of active drug in tumour cells. Such a strategy would overcome the various pharmacokinetic constraints of targeting monoclonal antibodies (Jain, 1991) when they are directly coupled to the drug or toxin. Generated active drug would be free to diffuse into surrounding cancer cells, without the need for antibody internalisation, and this would address the problem of tumour antigen heterogeneity. Antibody-directed enzyme prodrug therapy (ADEPT) aims at this goal (Bagshawe et al., 1988; Senter et al., 1988) and depends on the selective binding of an antibody–enzyme conjugate by tumour followed by enzymic conversion of the prodrug to the cytotoxic species.

This approach has been successfully tested by measuring tumour growth delay in mice bearing choriocarcinoma (Springer et al., 1991) or colon tumour xenografts (Sharma et al., 1991; Blakey et al., 1993) using the prodrug 4-(2-chloroethyl)(2-mesyloxyethyl)amino-benzoyl-L-glutamate, which is deglutamylated to a cytotoxic benzoic acid mustard by the bacterial enzyme carboxypeptidase G₂ (CPG₂). The conjugate, consisting of CPG₂ coupled to either anti-hCG or anti-CEA antibodies, was injected at least 3 days before the prodrug to avoid toxicity due to turnover by residual enzyme conjugate in the blood. The use of ADEPT has enabled a 2-fold higher concentration of active drug in tumour to be achieved (over the concentration time curve 5–60 min) compared with that obtained by direct drug administration (unpublished data). The therapeutic efficiency and specificity, however, are still limited owing to conversion of prodrug in normal tissues by residual enzyme conjugate. Further decay of enzyme activity from normal tissues takes place after 3 days, but this is also accompanied by loss of enzyme conjugate from the tumour site. A three-phase ADEPT system incorporating an enzyme clearance stage has therefore been developed and greatly reduces circulatory residual enzyme and the toxicity that ensues (Sharma et al., 1990). In this approach a galactosylated anti-CPG₂ monoclonal antibody (SB43-GAL) capable of inactivating the enzyme was injected 19 h after the conjugate and before the prodrug which was given at 24 h. Residual enzyme conjugate reacted with the anti-enzyme clearing antibody aiding its removal to the liver and allowing prodrug to be administered earlier. Although SB43-GAL effectively reduced the concentration of conjugate in blood, its effect on the bio-distribution of the conjugate in other tissues and the rate of prodrug turnover is unknown. It is important to optimise this in favour of tumour site-specific prodrug activation especially if short half-life, more reactive, drug species are employed. In the studies reported here we have employed different three regimens using the monoclonal anti-CPG₂ clearing antibody (SB43) to investigate its effect on in vivo generation of active drug in tissues of mice bearing the colon tumour xenograft LS174T and given anti-CEA-CPG₂ localising conjugate.

Materials and methods

Conjugates and antibodies

Anti-CEA—carboxypeptidase G₂ conjugate CPG₂, a folate-depleting bacterial enzyme was covalently coupled to the F(ab)₂ fragment of the anti-CEA monoclonal antibody A587, employing a stable thioether linkage as described by Melton et al. (1993). Enzymic activity was determined by the spectrophotometric assay as described by McCulloch et al. (1971).

Antibodies SB43, an IgG₂ anti-CPG₂ monoclonal antibody, was raised in Balb/C mice immunised with 50 µg of CPG₂ and has been shown to inhibit the enzyme activity of CPG in vitro (Sharma et al., 1990). SB43 was galactosylated according to a modification of the method of Mattes (1987). Briefly, cyanomethyl tetra-O-acetyl-1-thiogalactopyranoside (400 mg) was reacted with sodium methoxide (5.4 mg) in anhydrous methanol at 20°C for 48 h. SB43 in 0.25% sodium borate buffer, pH 8.5, was added to the galactose derivative (10 µg of derivative to 200 µg of SB43) after evaporation of the methanol. After shaking at 20°C for 2 h the galacto-
sylated antibody was dialysed against three changes of phosphate-buffered saline (PBS).

**Drugs**

The prodrug 4-[[2-chloroethyl]amino]benzoyl-l-glutamic acid was synthesised by reaction of benzoinic acid mustard chloride (Rons NF et al, 1955) with l-glutamic acid diethyl ester (Bachem), followed by catalytic hydrogenation (Pd/C). This prodrug is readily cleaved by CPG2 to the parent mustard 4-[[2-chloroethyl]amino]benzoic acid (Springer et al., 1990). This prodrug–active drug pair was chosen for this study since they are stable at 0°C in aqueous media and can be efficiently and reproducibly extracted from tissues at this temperature. The chemical half-lives at 37°C in PBS (pH 7.4) for the prodrug and parent drug are 26 h and 10 h respectively (Antoniw et al., 1990).

**In vivo studies**

These were carried out in Nu/Nu mice bearing the human colon adenocarcinoma xenograft LS174T using tumours between 0.08 and 0.4 g. Typically, mice were injected (i.v.) with 50 units of A587-F(ab')2–CPG2 conjugate and given prodrug (i.p. 400 mg·kg⁻¹) 72 h later. In mice receiving antienzyme clearing antibody three regimens were employed in which SB43-GAL was given 19 h after the conjugate. In regimen 1 prodrug was given (i.p. 400 mg·kg⁻¹) at 5 h after SB43-GAL as in the standard protocol. In regimens 2 and 3 a shortened and extended clearance time was used respectively where prodrug was administered 0.5 h, or 53 h after the SB43-GAL. In these mice sufficient SB43-GAL (usually 250 µg) was administered intravenously to lower the blood enzyme concentration to <0.1 units·ml⁻¹. The prodrug was prepared for injection by dissolving in 10% dimethyl sulfoxide (DMSO) in sodium bicarbonate solution (1.2%). Groups of 4–6 mice were killed at 5, 15, 30, 60 and 120 min after the prodrug injection and the tissues (tumour, blood, liver, kidney, lung and spleen) collected in preweighed tubes and stored at −70°C.

**Drug extraction procedure**

The frozen tissues were immersed in 2 ml of 2% hydrochloric acid containing 0.25% sodium dodecyl sulphate (SDS) to denature any residual enzyme and quickly cut up into small pieces while still immersed, to form a fine suspension. A homogenate was formed by grinding with a spatula and then sonicated for 75 s while cooling in ice. The sonicate was centrifuged at 3500 r.p.m. for 30 min and the supernatant put through a prewashed (3 ml of methanol and 10 ml of 2 mM hydrochloric acid) C₂₅ Sep-Pak column (Waters Associates, UK). This was washed with 2 mM hydrochloric acid (3 ml) and the bound drugs eluted with methanol (BDH, HiPerSolv, 3 ml). The samples were dried in vacuo and reconstituted in 0.25 ml of mobile phase (see below) before analysis by high-performance liquid chromatography (HPLC). Extraction recoveries were greater than 80% for the prodrug and greater than 90% for the active drug, similar to those in our previous study (Antoniw et al., 1990) employing lower doses of produgs.

Tests were carried out to quantify possible prodrug turnover by enzyme present in tissues and also possible hydrolysis of the chlorine atoms after removal of tissues from the mice. This was done by portioning tissues and keeping aliquots at −70°C and immersed in ice for 24 h until the drugs were extracted. There was no significant difference in extractable residual prodrug or active drug in this experiment. Moreover, the peak areas for the hydrolysis products were unchanged although these were negligible compared with those of the intact drugs being studied. Tissues which were kept at 37°C, however, showed a reduction in the concentration of prodrug (approximately 18%) and increased amounts of the hydrolysis products which were identified by their short retention times (<3 min). Studies by Antoniw et al. (1990) are in agreement, showing negligible prodrug turnover at the in vitro stage following the extraction procedure described above.

HPLC analysis was performed using a Waters system. This consisted of a model 600A solvent pump, a Wisp 712 autoinjector and a model 480 variable wavelength detector set at 305 nm. The separation was performed on a Waters C₁₈ Bondapak column (100 × 5 mm, 5 µm particle size) with a guard column of pellicular C₁₈ material. The mobile phase was 35% acetonitrile in water containing 1% acetic acid. The retention times for the prodrug and active drug were 4.9 and 12.3 min respectively when the flow rate was set at 1 ml min⁻¹. Standard lines for both drugs were determined using mouse serum spiked with drug standards and extracted as described above. Peak areas were computed using Maxima (Millipore) or EZChrom (Scientific Software) chromatography data systems. Drug concentrations are expressed as µg·g⁻¹ of tissue. Tissues from individual mice were extracted separately and the mean data/group calculated together with the percentage coefficient of variation. The drug concentrations in the xenografts were found to be independent of the tissue size and weight.

**Results**

**Regimen 1: 5 h clearance time**

The standard protocol for using SB43-GAL clearance has been to give this 19 h after the enzyme conjugate when sufficient SB43-GAL was administered to reduce circulatory enzyme levels to <0.1 units·ml⁻¹ of blood (Sharma et al., 1994). Prodrug was then administered at 20 or 24 h after the conjugate without toxicity. In regimen 1 prodrug was injected i.p. 24 h after the conjugate at a dose of 400 mg·kg⁻¹. The concentrations of generated active drug measured in blood, liver and tumour for this regimen are shown in Figure 1. Prodrug was converted most efficiently in the liver where the peak concentration of active drug reached 340 µg·g⁻¹ at 15 min after injection. The peak concentrations of active drug in tumour and blood, reaching 140 µg·g⁻¹ and 199 µg
g\textsuperscript{−1} respectively, were appreciably lower than that in the liver. At time points beyond 5 min these levels are broadly equivalent to those of the control where prodrug was administered 72 h after the conjugate without SB43-GAL, Figure 2. Here the peak concentrations of active drug in the liver, tumour and blood reached 350, 160 and 210 µg g\textsuperscript{−1} respectively. At the 5 min time point, however, SB43-GAL resulted in lower active drug levels in blood and liver compatible with a slower rate of prodrug turnover. To give prodrug safely at 24 h after the conjugate without SB43-GAL necessitated using a lower dose (a dose of 200 mg kg\textsuperscript{−1} of prodrug was used for these experiments) and the extrapolated peak values for the active drug in liver, tumour and blood were similar to those when SB-43-GAL was used (data not shown). Regimen 1, although allowing early administration of prodrug, resulted in marginally poorer tumour–blood and tumour–liver ratios for active drug at time points up to 60 min (Figure 3). There was also no obvious improvement in the availability of active drug at the tumour site at the time points studied, compared with the 72 h control.

Regimen 2: 0.5 h clearance time

An experiment was carried out in which prodrug was administered 0.5 h after the SB43-GAL and the tissue levels of generated active drug measured, (Figure 4). Compared with the control, Figure 2, there was a reduced concentration of active drug in the blood (approximately 50% of that in the control) up to 30 min after injection, although there was also a reduction associated with the tumour which was severe up to 5 min after injection of the prodrug. This resulted in slightly poorer tumour-blood ratios (Figure 5a). Liver levels of active drug, in contrast, were much higher than the control and tumour–liver ratios for active drug were poor (Figure 5b).

Regimen 3: 53 h clearance time

Increasing the SB43-GAL clearance time to 53 h (prodrug administered 72 h after the conjugate) resulted in the lowest concentrations of active drug in the tissues, Figure 6. For example, the peak concentration of active drug associated with the tumour was over 60% lower than the corresponding levels of the 72 h control. However, when SB43-GAL was used, active drug concentrations in tumour were higher at most time points than the five normal tissues selected for this study. Comparative tumour–normal tissue ratios are shown in Figure 7.
Residual prodrug

The data for the residual prodrug remaining in tissues for the three clearance regimens (Figure 8) is consistent with the clearance of conjugate from the blood to the liver. Thus, in regimen 1 (Figure 8a) measurable prodrug in blood remained up to 1 h after injection and the concentration of prodrug in the liver also remained high up to 30 min after injection. In regimen 2 (Figure 8b), however, rapid transport of conjugate from the blood to the liver resulted in similar residual prodrug in blood but a much reduced level in the liver due to extensive prodrug turnover. Regimen 3 resulted in the highest concentration of residual prodrug in both blood and liver (Figure 8c). Residual prodrug in the tumour was not altered by SB43-GAL clearance and was depleted at a similar rate in all regimens.

Discussion

The anti-carboxypeptidase G2 monoclonal antibody (SB43) was developed to reduce the concentration of circulating antibody enzyme conjugate in ADEPT. Our previous studies (Sharma et al., 1990) demonstrated that SB43 could bind to carboxypeptidase G2, causing loss of enzyme activity and as such should be an ideal agent to quell circulating enzyme and blood-borne activation of prodrug. To reduce possible inactivation of enzyme at the tumour site, SB43 was covalently linked to galactose to facilitate its rapid uptake by receptors in the liver and minimise the circulatory dwell time. Given to mice bearing the LS174T colon tumour xenograft 19 h after the conjugate, SB43 linked to galactose had the predicted effect of reducing CPG2 concentrations in the blood without appreciably affecting the concentration of enzyme at the tumour site (Sharma et al., 1990, 1991, 1994). This regimen allowed therapy doses of prodrug to be injected within 24 h of giving the conjugate. Using the above protocol (regimen 1) the present studies have confirmed that SB43-GAL enables prodrug to be administered 24 h after the conjugate without toxicity and without appreciably altering the concentration of active drug found in the tumour. Consistent with this, our data for regimen 1 also shows an overall lower concentration of active drug in blood at the 5 min time point together with a higher level of residual prodrug compared with the control (data not shown). Moreover, at later time points, active drug levels in blood were similar to the 72 h control. This suggests that SB43-GAL had the predicted effect of reducing blood enzyme and reducing the rate of circulatory prodrug turnover at 24 h after administration of the conjugate, to a level similar to that at 72 h when SB43-GAL was not used. The
logistical advantage of this has been demonstrated in experimental therapy studies (Sharma et al., 1991, 1994) and SB43-GAL has been applied in clinical investigations in which, given as an infusion, it successfully reduced plasma enzyme concentrations and toxicity (Bagshawe et al., 1991). Anti-enzyme clearance is therefore a viable approach which has been similarly applied for the circulatory clearance of cytosine deaminase immunoconjugate (Kerr et al., 1993). It therefore supplements other recently described clearance systems including modification of conjugates with sugars

![Graph 1](image1)

![Graph 2](image2)

**Figure 6** Tissue concentrations of generated active drug (a) in mice given A5-CPG2 followed by SB43-GAL at 19 h and prodrug at 72 h (regimen 3) and (b) in mice given A5-CPG2 and prodrug only. O, blood; □, liver; ▲, tumour; ○, kidney; ▼, lung; *, spleen. Each data point represents the mean 4–6 mice with the coefficient of variation ranging from 6% to 14.6% for blood; from 8% to 19.9% for liver, from 10% to 17% for tumour and from 3% to 18.6% for kidney, lung and spleen.

![Graph 3](image3)

**Figure 7** Tissue-normal tissue ratios of generated active drug in mice (solid symbol) given A5-CPG2 followed by SB43-GAL at 19 h and prodrug at 72 h (regimen 3) and in mice (open symbol) given A5-CPG2 and prodrug only.
Depletion of residual prodrug from the liver is somewhat faster when SB43-GAL anti-enzyme clearance is used, suggesting that SB43-enzyme conjugate complexes in this organ are capable of dissociation, thus supplementing enzyme activity already present in the liver. This appears not to be a problem when regimen 1 is used since the level of active drug in liver appears to be similar to that of the control. Thus, within the 5 h clearance time, free SB43-GAL can cause progressive inactivation of conjugate and facilitate its degradation and excretion. It is important to note that prodrug turnover at the tumour site is not improved by earlier administration of prodrug. An improvement might have been expected owing to the higher concentration of localised enzyme at 24 h (Sharma et al., 1990), however, pharmacokinetic studies to address this question (unpublished data) have shown that prodrug turnover in tumour is more likely to be limited by prodrug availability rather than an insufficient concentration of targeted enzyme.

Further insight into the mechanism of SB43-GAL clearance can be inferred from the study in which prodrug turnover was examined within half an hour of the SB43-GAL injection (regimen 2). Here, in contrast to the standard regimen, levels of active drug associated with the liver are several-fold higher than that of the control. This is consistent with effective clearance of anti-enzyme–enzyme complexes via galactose-receptor-mediated uptake to the liver and subsequent dissociation, thus deactivating the enzyme. Extensive turnover of prodrug would then be expected leading to the observed high active drug levels. Moreover, this regimen showed the fastest depletion of prodrug in the liver, resulting in a much lower peak concentration compared with regimen 1 (Figure 8b). In contrast to the liver, the disappearance of residual prodrug in the blood was markedly slower, consistent with effective clearance of the conjugate and removal of enzyme from this tissue. These results show that while anti-enzyme can remove circulating enzyme to advantage in ADEPT, binding to the enzyme is reversible in the liver and could lead to undesirable feedback of active drug into the blood. It appears, however, that enzyme complexes are also capable of degradation and excretion within a period of hours (see regimen 1) and consequently timing of prodrug administration is a key factor for the optimisation of ADEPT.

In the third study (regimen 3) prodrug was administered 3 days after the conjugate (53 h after SB43-GAL). Under these conditions the concentration of active drug associated with all tissues was lower. For example, the concentration of active drug in the tumour peaked at 60 μg g⁻¹, about two and a half times lower than that of the control. This was expected as the concentration of A5-CPG₃ would be decreased by the combined effects of SB43-GAL-accelerated clearance and natural decay of the conjugate. However, at most time points, there was more active drug in the liver than in the normal tissues, showing that prodrug turnover at this site was favoured. With the prospect of increasing the dosage of prodrug in regimen 3 it should still be possible to attain a higher level of active drug in tumour by ADEPT than by direct administration of the active drug.

Residual prodrug levels in the tumour were not affected by SB43-GAL in all three regimens (Figure 8a, b and c). This was expected, as our earlier studies (Sharma et al., 1994) showed that the galactose moiety caused rapid removal of conjugate from the blood, leaving the targeted enzyme at the tumour site largely unaffected. The lower active drug levels in tissues for regimen 3 (compared with regimens 1 and 2) are consistent with a more complete clearance and degradation of enzyme activity over the extended time interval.

Figure 8 Concentrations of residual prodrug in blood (O), liver (D) and tumour (A) of mice given A5-CPG₃ followed by SB43-GAL at 19 h and prodrug at (a) 24 h, (b) 19.5 h and (c) 72 h. The data represent the mean of 4–6 mice. The coefficient of variation for all the groups ranged from 4.1% to 26%.

(Sharma et al., 1994), use of anti-idiotypes or second antibodies (Pedley et al., 1989) and use of biotin–avidin constructs (Paganelli et al., 1991).
feedback of active drug into the blood, however, may be
controlled by appropriate timing of the prodrug injection. In
addition, our data suggest that an extended anti-enzyme
clearance schedule may enable much larger doses of prodrug
to be used with improved tumour site-specific turnover.

References

ANTONIW P, SPRINGER CJ, BAGSHAWE KD, SEARLE F, MELTON
RG, ROGERS GT, BURKE PJ AND SHERWOOD RF. (1990). Dis-
position of the prodrug 4-[bis(2-chloroethyl)amino]benzoyl-L-
glutamic acid and its active parent drug in mice. Br. J. Cancer,
62, 909–914.

BAGSHAWE KD. (1987). Antibody directed enzymes revive anti-
cancer prodrug concept. Br. J. Cancer, 56, 531–532.

BAGSHAWE KD, SPRINGER CJ, SEARLE F, ANTONIW P, SHARMA
SK, MELTON RG AND SHERWOOD RF. (1988). A cytotoxic agent
can be generated selectively at cancer sites. Br. J. Cancer, 58,
700–703.

BLAKEY DC, VALCACCIA BE, EAST S, WRIGHT AF, BOYLE FT,
SPRINGER CJ, BURKE PJ, MELTON RG AND BAGSHAWE KD.
(1993). Anti-tumour effects of an antibody–carboxypeptidase G2
conjugate in combination with a benzoic acid mustard prodrug.
Cell Biophysics, 222, 1–8.

JAIN RK. (1991). Haemodynamic and transport barriers to the treat-
ment of solid tumours. Int. J. Radiat. Biol., 60, 85–100.

KERR DE, GARRIGUES US, WALLACE PM, HELLSTROM KE, HELL-
STROM I AND SENTER PD. (1993). Application of monoclonal
antibodies against cytosine deaminase for the in vivo clearance
of a cytosine deaminase immune conjugate. Bioconjugate Chem.,
4, 353–357.

McCulloch JL, Chabner BA AND BERTINO JR. (1971). Purification
and properties of carboxypeptidase G2. J. Biol. Chem., 246,
7207.

MATTES MJ. (1987). Biodistribution of antibodies after intra-
peritoneal or intravenous injection and effect of carbohydrate
modifications. J. Natl Cancer Inst., 79, 855–863.

MELTON RG, BOYLE JMB, ROGERS GT, BURKE PJ, BAGSHAWE KD
AND SHERWOOD RF. (1993). Optimisation of small–scale coupling
of A5B7 monoclonal antibody to carboxypeptidase G2. J.
Immunol. Methods., 158, 49–56.

PAGANELLI G, MALCOVATI M AND FAZIO F. (1991). Monoclonal
antibody pretargeting techniques for tumour localisation: The
avidin–biotin system. Nucl. Med. Commun., 12, 211–234.

PEDLEY RB, DALE R, BODEN JA, BEGENT RH, KEEP PA AND
GREEN AJ. (1989). The effect of second antibody clearance on the
distribution and dosimetry of radiolabeled anti-CEA antibody
in a human colon tumour xenograft model. Int. J. Cancer, 43,
713–718.

ROSS WCI, WARWICK GP AND ROBERTS JJ. (1955). Aril-2-halo-
genoaalkylamines. Part XIV. Some compounds possessing latent
cytotoxic activity. J. Chem. Soc., 3110–3116.

SENTER PD, SAULNIER MG, SCHREIBER GJ, HIRSCHBERG DL,
BROWN JP, HELLSTROM I AND HELLSTROM KE. (1988). Anti-
tumour effects of antibody–alkaline phosphatase conjugates in
combination with etoposide phosphate. Proc. Natl Acad. Sci.
U.S.A., 85, 4842–4846.

SHARMA SK, BAGSHAWE KD, BURKE PJ, BODEN RW AND
ROGERS GT. (1990). Inactivation and clearance of an anti-CEA
carboxypeptidase G2 conjugate in blood after localisation in a
xenograft model. Br. J. Cancer, 61, 659–662.

SHARMA SK, BAGSHAWE KD, SPRINGER CJ, BURKE PJ, ROGERS
GT, BODEN JA, ANTONIW P, MELTON RG AND SHERWOOD RF.
(1991). Antibody-directed enzyme prodrug therapy (ADEPT): a
three phase system. Disease Markers, 9, 225–231.

SHARMA SK, BAGSHAWE KD, BURKE PJ, BODEN JA, ROGERS GT,
SPRINGER CJ, MELTON RG AND SHERWOOD RF. (1994). Galac-
tosylated antibodies and antibody–enzyme conjugates in anti-
body-directed enzyme prodrug therapy. Cancer, 73, (suppl.)
1114–1120.

SPRINGER CJ, ANTONIW P, BAGSHAWE KD, SEARLE F, BISSET
GMP AND JARMAN M. (1990). Novel prodrugs which are
activated to cytotoxic alkylating agents by carboxypeptidase G2,
J. Med. Chem., 33, 677–681.

SPRINGER CJ, BAGSHAWE KD, SHARMA SK, SEARLE F, BODEN JA,
ANTONIW P, BURKE PJ, ROGERS GT, SHERWOOD RF AND
MELTON RG. (1991). Ablation of human chorionic carcinoma xenog-
rafts in nude mice by antibody-directed enzyme prodrug therapy
(ADEPT) with three novel compounds. Eur. J. Cancer, 27,
1361–1366.